GLAXOSMITHKLINE PLC Form 6-K August 01, 2008

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending August 01, 2008

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

--

GlaxoSmithKline plc received on 31 July 2008 from Legal & General Group plc a notification of interests in GlaxoSmithKline plc Ordinary shares of 25 pence each , dated 31 July 2008 . This notice is given in

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

accordance with DTR 5.8.12.

TR-1: notification of major interests in shares

1. Identity of the issuer or the underlying issuer					
of existing shares to which voting rights are	GlaxoSmithKline Plc				
attached:					
2. Reason for notification (yes/no)					
An acquisition or disposal of voting rights	Yes				
An acquisition or disposal of financial instruments which may result in the					
acquisition of shares already issued to which voting	rights are attached				
An event changing the breakdown of voting rights					
Other (please specify):					
3. Full name of person(s) subject to the	Legal & General Group Plc (Group)				
notification obligation:	Legal & General Investment Management Limited				
	(LGIM)				
4. Full name of shareholder(s) (if different from	Legal & General Assurance (Pensions Management)				
3.):	Limited (PMC)				
	Legal & General Group Plc (L&G)				
5. Date of the transaction (and date on which the	30 July 2008				
threshold is crossed or reached if different):					
6. Date on which issuer notified:	31 July 2008				
7. Threshold(s) that is/are crossed or reached:	Below 5% (Group)				
	Below 5% (LGIM)				

8. Notified details:

A: Voting rights attached to shares Class/typeSituation previous toResulting situation after the triggering transaction of shares the Triggering transaction							
if possible using the ISIN CODE	_e Shares	Number of Voting Right	Number o ^s shares	fNumber rights	of voting	g% of votir	ıg rights
ORD GBP0.25	283,832,153	283,832,153		Direct	Indirect Below 5%	Direct	Indirect
B: Financia	l Instrument	S					

Resulting situation after the triggering transactionType of financial Expiration date
instrumentExercise/ Conversion
Period/ DateNumber of voting% of voting
rights that may berights
a cquired if the
instrument is
exercised/ converted.

Total (A+B) Number of voting rights

% of voting rights Below 5%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

Legal & General Group Plc (Direct and Indirect) (Group) (Below 5%) Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) (Below 5%) Legal & General Investment Management Limited (Indirect) (LGIM) (Below 5%) Legal & General Group Plc (Direct) (L&G) (244,009,760 - 4.65 % = LGAS, LGPL & PMC) Legal & General Investment Legal & General Insurance Holdings Limited Management (Holdings) Limited (Direct) (LGIH) (Direct) (LGIMHD) (200,360,654 - 3.82 % = PMC) Legal & General Assurance (Pensions Legal & General Assurance Society Limited (LGAS & LGPL) Management) Limited (PMC) (200,360,654 - 3.82 % = PMC) Legal & General Pensions Limited (Direct) (LGPL)

Proxy Voting:	
10. Name of the proxy holder:	N/A
11. Number of voting rights proxy holder will cease to	N/A
hold:	
12. Date on which proxy holder will cease to hold	N/A
voting rights:	

13. Additional information:	Notification using the total voting rights figure of 5,240,433,283
14. Contact name:	Helen Lewis (LGIM)
15. Contact telephone number:	020 3124 3851

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: August 01, 2008

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc